Introduction {#s1}
============

Over the past three decades, there has been a global increase in the prevalence of obesity, which has been mainly driven by changes in lifestyle [@pmed.1001116-World1]. However, not everyone becomes obese in today's obesogenic environment. In fact, twin studies suggest that changes in adiposity in response to environmental influences are genetically determined [@pmed.1001116-Bouchard1]--[@pmed.1001116-Silventoinen1]. Until recently, there were no confirmed obesity-susceptibility loci that could be used to test whether the influence of genetic susceptibility on obesity risk is enhanced by an unhealthy lifestyle. However, in 2007, the intron 1 of the fat mass and obesity associated (*FTO*) gene was identified as the first robust obesity-susceptibility locus in genome-wide association studies [@pmed.1001116-Frayling1],[@pmed.1001116-Scuteri1]. Each additional minor allele of the rs9939609 single nucleotide polymorphism (SNP) in *FTO* was found to be associated with a 20%--30% increase in the risk of obesity and a 1--1.5 kg increase in body weight [@pmed.1001116-Frayling1],[@pmed.1001116-Scuteri1]. The risk-increasing allele of *FTO* is common, with 74% of individuals of European descent (HapMap CEU population), 76% of individuals of African-American descent (HapMap ASW population), and 28%--44% of individuals of Asian descent (HapMap CHB, CHD, GIH, and JPT populations) carrying at least one copy of the *FTO* risk allele.

After the discovery of *FTO*, several studies reported that its obesity-increasing effect may be attenuated in individuals who are physically active [@pmed.1001116-Andreasen1]--[@pmed.1001116-Ahmad1]. Other studies, however, were unable to replicate this interaction [@pmed.1001116-Jonsson1]--[@pmed.1001116-Tan1], leaving it unresolved whether physical activity (PA) can reduce *FTO*'s effect on obesity risk, and if so, to what extent. Identifying interactions between genetic variants and lifestyle is challenging as it requires much larger sample sizes than those needed for the detection of main effects of genes or environment [@pmed.1001116-Smith1]. Interaction studies are further hampered by the difficulty of measuring lifestyle exposures accurately, which reduces statistical power and necessitates large study sample sizes to offset this effect [@pmed.1001116-Wong1].

To collect a sufficiently large sample to unambiguously confirm or refute the interaction between *FTO* and PA, we meta-analyzed data from 45 studies, totaling 218,166 adults. In addition, we performed a similar meta-analysis among 19,268 children and adolescents from nine studies. We included all available data, both published and unpublished, and used standardized methods to analyze the interaction across the studies.

Methods {#s2}
=======

Ethics Statement {#s2a}
----------------

All studies were conducted according to the Declaration of Helsinki. Informed consent was obtained from all participants, and the studies were approved by the ethics committees of the participating institutions.

Study Design {#s2b}
------------

The literature on the interaction between *FTO* and PA is inconsistent with regard to the definitions used for PA, the statistical analysis of interactions, and the presentation of interaction results [@pmed.1001116-Palla1]. Furthermore, as statistically non-significant interactions may often not be reported, a meta-analysis of only published results would suffer from publication bias [@pmed.1001116-Palla1]. Therefore, a literature-based meta-analysis of the interaction between *FTO* and PA was not considered appropriate. Instead, we designed a meta-analysis based on de novo analyses of data according to a standardized plan to achieve the greatest consistency possible across studies, and to allow inclusion of all available studies, irrespective of whether they had or had not been used to examine this hypothesis in the past.

We identified all eligible studies by a PubMed literature search in December 2009 using the search term "FTO" and by following the publication history of each identified study to find those with data on PA. Furthermore, we identified all studies with genome-wide association data from published papers of genome-wide association consortia by a PubMed search using the keywords "genome-wide" and "association," and searched the literature to determine whether these studies also had data on PA. Additional yet-unpublished studies were identified through the network of collaborators who joined the meta-analysis and were also included in the meta-analysis. Analyses according to our standardized plan were performed by each study locally, and detailed summary statistics were subsequently submitted using our standardized data collection form. Alternatively, datasets were sent to us to perform the required analyses centrally (15 studies) ([Tables S1](#pmed.1001116.s010){ref-type="supplementary-material"} and [S2](#pmed.1001116.s011){ref-type="supplementary-material"}).

Quality Control {#s2c}
---------------

The data collection form included questions that allowed testing for internal consistency. The data were extracted automatically and cross-checked manually. The same checks for internal consistency were performed independent of whether the data were analyzed locally or centrally. All ambiguities were clarified with the respective study investigators before the final meta-analyses. A funnel plot, along with Begg and Egger tests, was used to test for the presence of "positive results bias" (i.e., to test whether studies with positive results were more likely to participate in the meta-analysis than those with negative or inconclusive results) ([Figure S1](#pmed.1001116.s001){ref-type="supplementary-material"}).

Standardization of Physical Activity {#s2d}
------------------------------------

PA was measured in various ways across the participating studies of the meta-analysis. Therefore, we standardized PA by categorizing it into a dichotomous variable (physically inactive versus active) in each study. In studies with categorical PA data, adults were defined as being "inactive" when they had a sedentary occupation and if they reported less than 1 h of moderate-to-vigorous leisure-time or commuting PA per week. In studies with continuous data on PA, adults were defined as being "inactive" when their level of PA was in the lowest sex-specific 20% of the study population concerned. All other individuals were defined as "physically active." For children and adolescents, a more stringent cut-off for "inactivity" was chosen than for adults because of the high average PA levels in younger children [@pmed.1001116-Troiano1] and the known weaker association between PA and childhood body mass index (BMI) [@pmed.1001116-Ekelund1]. Thus, children and adolescents were defined as being "inactive" when their level of PA was in the lowest sex- and age-specific 10% of the study population. The coding of the dichotomous PA variable in each study is described in detail in [Text S1](#pmed.1001116.s015){ref-type="supplementary-material"}.

Genotyping {#s2e}
----------

The rs9939609 SNP or a proxy (linkage disequilibrium *r* ^2^\>0.8 in the corresponding ethnic group) was genotyped in each study using either direct genotyping methods or Affymetrix and Illumina genome-wide genotyping arrays ([Text S1](#pmed.1001116.s015){ref-type="supplementary-material"}). The studies submitted only data that met their quality control criteria for genotyping call rate, concordance in duplicate samples, and Hardy-Weinberg Equilibrium *p-*value ([Text S1](#pmed.1001116.s015){ref-type="supplementary-material"}).

Measurement of BMI, Waist Circumference, and Body Fat Percentage {#s2f}
----------------------------------------------------------------

BMI was calculated in each study by dividing height (in meters) by weight (in kilograms) squared. Waist circumference was measured with standard protocols and was not adjusted for height in the analyses. Body fat percentage was measured using dual energy X-ray absorptiometry (seven studies), bioimpedance (11 studies), or the sum of skinfolds (seven studies) ([Tables S3](#pmed.1001116.s012){ref-type="supplementary-material"} and [S4](#pmed.1001116.s013){ref-type="supplementary-material"}).

*FTO*×PA Interaction Analysis in Participating Studies {#s2g}
------------------------------------------------------

Each study tested for an effect of the *FTO*×PA interaction on BMI, waist circumference, and body fat percentage using the following additive genetic model:

The same model was used to test for an effect of the *FTO*×PA interaction on the odds of obesity (BMI≥30 versus BMI\<25 kg/m^2^) and overweight (BMI≥25 versus BMI\<25 kg/m^2^) in adults, using normal-weight individuals as the reference group and testing for an additive effect in the "log odds" scale. In addition, each study tested the main effect of the *FTO* SNP on each outcome in the whole study population and in the inactive and physically active subgroups separately, using the model

Each study also tested the main effect of PA on each outcome, using the model

The interactions and associations of continuous outcome variables were analyzed with linear regression and those of dichotomous variables with logistic regression. In adults, BMI, waist circumference, and body fat percentage were analyzed as non-transformed variables, whereas in children, age- and sex-specific *Z*-scores of BMI, waist circumference, and body fat percentage were used.

Where data were from case-control studies for any outcome ([Tables S1](#pmed.1001116.s010){ref-type="supplementary-material"} and [S2](#pmed.1001116.s011){ref-type="supplementary-material"}), cases and controls were analyzed separately. In studies with multiple ethnicities, each ethnicity was analyzed separately.

Meta-Analysis and Meta-Regression {#s2h}
---------------------------------

Because of heterogeneity between the studies participating in the meta-analysis, we pooled beta coefficients and standard errors for the main and interaction effects from individual studies using "DerSimonian and Laird" random effects meta-analysis, implemented by the *metan* command in Stata, version 11 (StataCorp). To confirm that our results were robust, we additionally pooled the interaction effects using the "Mantel and Haenszel" fixed effects method in Stata. However, as beta coefficients of fixed effects models and random effects models were the same (to two decimal points' accuracy) for all traits, we report only the results for the random effects models. Data from adults and children were meta-analyzed separately. In all meta-analyses, between-study heterogeneity was tested by the *Q* statistic and quantified by the *I* ^2^ value. Low heterogeneity was defined as an *I* ^2^ value of 0%--25%, moderate heterogeneity as an *I* ^2^ of 25%--75%, and high heterogeneity as an *I* ^2^ of 75%--100% [@pmed.1001116-Higgins1].

We performed a meta-regression to explore sources of heterogeneity in our meta-analysis using the *metareg* command in Stata. Meta-regression included the following study-specific variables as covariates: study sample size, proportion of inactive individuals, age (mean age or age group \<60 y versus ≥60 y), sex (male versus female), mean BMI, study design (population- or family-based versus case-control), self-reported ethnicity (white, African American, Asian, Hispanic), geographic region (North America, Europe, Asia), and measurement of PA (1: studies with a continuous PA variable versus studies with categorical data; 2: measurement of both occupational and leisure-time PA versus leisure-time PA only; 3: measurement of PA with a questionnaire versus objective measurement).

Differences in interaction effect sizes between two subgroups were assessed with a *t*-test.

Results {#s3}
=======

Studies Included {#s3a}
----------------

Our literature search identified 47 studies with data available on *FTO* and PA, of which 41 agreed to participate in our meta-analysis ([Figure 1](#pmed-1001116-g001){ref-type="fig"}). Furthermore, 14 additional yet-unpublished studies that were identified through the network of collaborators who joined the meta-analysis were also invited to participate in the meta-analysis. We excluded one of these studies, however, because of inadequate measurement of PA. Eventually, our final meta-analysis comprised cross-sectional data on 218,166 adults (209,118 whites, 6,309 Asians, 1,770 African-Americans, and 969 Hispanics) from 45 studies, as well as data on 19,268 white children and adolescents from nine studies. Of the 45 studies of adults, 33 were from Europe, ten from North America, and two from Asia. All studies of children and adolescents were from Europe. In each study, PA was assessed using a self-report questionnaire, an accelerometer, or a heart rate sensor ([Text S1](#pmed.1001116.s015){ref-type="supplementary-material"}).

![Study design of the *FTO*×PA interaction meta-analysis.\
Eligible studies were identified by a literature search, as well as through personal contacts (indicated in the figure as "other data"). Of all studies that were invited, 45 studies of adults (*n = *218,166) and nine studies of children and adolescents (*n = *19,268) joined the meta-analysis. A standardized analytical plan was sent to each of the studies. Summary statistics were subsequently meta-analyzed.](pmed.1001116.g001){#pmed-1001116-g001}

Association of Physical Activity with Obesity Traits (Main Effects) {#s3b}
-------------------------------------------------------------------

Physically active adults had a 33% lower odds of obesity (*p = *2×10^−13^), 19% lower odds of overweight (*p = *7×10^−9^), 0.79 kg/m^2^ lower BMI (*p = *3×10^−15^), 2.44 cm smaller waist circumference (*p = *1×10^−20^), and 1.30% lower body fat percentage (*p = *2×10^−15^) than inactive adults ([Table S1](#pmed.1001116.s010){ref-type="supplementary-material"}). In children, PA did not have a statistically significant association with age- and sex-standardized BMI (*p = *0.2), but physically active children had a waist circumference −0.11 *Z*-score units smaller (*p = *0.04) and a body fat percentage −0.21 *Z*-score units lower (*p = *0.02) than inactive children ([Table S2](#pmed.1001116.s011){ref-type="supplementary-material"}).

Association of *FTO* with Obesity Traits (Main Effects) {#s3c}
-------------------------------------------------------

In adults, each additional risk allele of the *FTO* rs9939609 variant increased the odds of obesity and overweight by 23% (*p = *7×10^−59^) and 15% (*p = *6×10^−66^), respectively ([Table 1](#pmed-1001116-t001){ref-type="table"}). The risk allele also increased BMI by 0.36 kg/m^2^ (∼1 kg in body weight for a person 170 cm tall) (*p = *2×10^−75^), waist circumference by 0.77 cm (*p = *5×10^−43^), and body fat percentage by 0.30% (*p = *2×10^−21^) ([Table 1](#pmed-1001116-t001){ref-type="table"}).

10.1371/journal.pmed.1001116.t001

###### Association of the minor (A−) allele of the rs9939609 SNP or a proxy (*r* ^2^\>0.8) in the *FTO* gene with BMI, waist circumference, body fat percentage, risk of obesity, and risk of overweight in a random effects meta-analysis of up to 218,166 adults.

![](pmed.1001116.t001){#pmed-1001116-t001-1}

  Trait                                                       Geographic Region     *N*     Beta or OR[1](#nt102){ref-type="table-fn"} (95% CI)    *p-*Value     *I* ^2^
  ---------------------------------------------------------- ------------------- --------- ----------------------------------------------------- -------------- ---------
  **BMI (kg/m^2^)**                                            All individuals    218,166                    0.36 (0.32, 0.40)                    1.8×10^−75^      34%
                                                                   Europe         164,307                    0.32 (0.29, 0.34)                    7.6×10^−110^     0%
                                                                North America     47,938                     0.42 (0.32, 0.53)                    1.4×10^−15^      31%
                                                                    Asia           5,921                     0.59 (0.33, 0.85)                     7.9×10^−6^      39%
  **Waist circumference (cm)**                                 All individuals    159,848                    0.77 (0.66, 0.87)                    5.4×10^−43^      28%
                                                                   Europe         128,811                    0.71 (0.60, 0.82)                    3.4×10^−37^      20%
                                                                North America     25,117                     0.89 (0.60, 1.17)                    7.5×10^−10^      17%
                                                                    Asia           5,920                     1.28 (0.69, 1.86)                     1.8×10^−5^      34%
  **Body fat percentage (%)**                                  All individuals    61,509                     0.30 (0.24, 0.36)                    2.2×10^−21^      1%
                                                                   Europe         60,617                     0.29 (0.23, 0.36)                    2.6×10^−21^      0%
                                                                North America       892                      0.79 (0.12, 1.47)                       0.021         0%
                                                                    Asia            NA                              NA                                 NA          NA
  **Risk of obesity (BMI ≥30 versus BMI \<25 kg/m^2^)**        All individuals    131,474                    1.23 (1.20, 1.26)                    7.2×10^−59^      28%
                                                                   Europe         97,877                     1.22 (1.19, 1.25)                    1.7×10^−47^      21%
                                                                North America     29,282                     1.26 (1.19, 1.33)                    3.3×10^−14^      33%
                                                                    Asia           4,315                     1.48 (1.25, 1.75)                     4.8×10^−6^      0%
  **Risk of overweight (BMI ≥25 versus BMI \<25 kg/m^2^)**     All individuals    213,564                    1.15 (1.13, 1.16)                    5.5×10^−66^      10%
                                                                   Europe         163,069                    1.14 (1.12, 1.16)                    5.6×10^−55^      5%
                                                                North America     44,574                     1.14 (1.09, 1.18)                    2.4×10^−10^      21%
                                                                    Asia           5,921                     1.26 (1.14, 1.40)                     4.9×10^−6^      0%

All models are adjusted for age and sex. Beta is the increase in trait per minor (A−) allele of rs9939609 or a proxy (*r* ^2^\>0.8); *I* ^2^ is the heterogeneity between studies in the association of rs9939609 with the trait.

Values are beta for all rows except risk of obesity and risk of overweight, for which values are OR.

NA, no data available for analysis.

In children and adolescents, each *FTO* risk allele increased age- and sex-specific BMI by 0.10 *Z*-score units (*p = *1×10^−21^), waist circumference by 0.11 *Z*-score units (*p = *8×10^−16^), and body fat percentage by 0.12 *Z*-score units (*p = *2×10^−11^) ([Table S3](#pmed.1001116.s012){ref-type="supplementary-material"}).

*FTO*×PA Interaction and Obesity Traits {#s3d}
---------------------------------------

### *FTO*×PA interaction and BMI {#s3d1}

PA significantly (beta~interaction~  =  −0.14 kg/m^2^ per allele, *p* ~interaction~  = 0.005) attenuated the association between the *FTO* variant and BMI in our meta-analysis of 218,166 adults ([Figure 2](#pmed-1001116-g002){ref-type="fig"}; [Table 2](#pmed-1001116-t002){ref-type="table"}) (i.e., a beta~interaction~ of −0.14 kg/m^2^ represents the difference in the BMI-increasing effect of the risk allele between physically active and inactive individuals). The magnitude of the effect of the *FTO* risk allele on BMI was 30% smaller in physically active individuals (beta  = 0.32 kg/m^2^) than in inactive individuals (beta  = 0.46 kg/m^2^) ([Table 2](#pmed-1001116-t002){ref-type="table"}).

![Forest plot of the effect of the interaction between the *FTO* rs9939609 SNP and physical activity on BMI in a random effects meta-analysis of 218,166 adults.\
The studies are sorted by sample size (largest sample size lowest). Details of the studies are given in [Text S1](#pmed.1001116.s015){ref-type="supplementary-material"}. The interaction beta represents the difference in BMI per minor (A−) allele of rs9939609 comparing physically active individuals to inactive individuals, adjusting for age and sex. For example, a beta~interaction~ of −0.10 kg/m^2^ for BMI represents a 0.10 kg/m^2^ attenuation in the BMI-increasing effect of the rs9939609 minor allele in physically active individuals compared to inactive individuals.](pmed.1001116.g002){#pmed-1001116-g002}

10.1371/journal.pmed.1001116.t002

###### Effect of the interaction between the rs9939609 SNP or a proxy (*r* ^2^\>0.8) and PA on BMI, waist circumference, body fat percentage, risk of obesity, and risk of overweight in a random effects meta-analysis of up to 218,166 adults.

![](pmed.1001116.t002){#pmed-1001116-t002-2}

  Trait                                                       Geographic Region   Main Effect of rs9939609 in Inactive Individuals   Main Effect of rs9939609 in Active Individuals   Rs9939609×PA Interaction                                                                                             
  ---------------------------------------------------------- ------------------- -------------------------------------------------- ------------------------------------------------ -------------------------- --------- -------------------- ------------- --------- ---------------------- ------------ -----
  **BMI (kg/m^2^)**                                            All individuals                         54,611                                      0.46 (0.37, 0.55)                        3.7×10^−23^          163,555   0.32 (0.29, 0.36)    4.5×10^−69^   218,166   −0.14 (−0.23, −0.04)     0.0049     36%
                                                                   Europe                              44,052                                      0.37 (0.31, 0.44)                        1.0×10^−26^          120,255   0.30 (0.27, 0.34)    2.4×10^−62^   164,307   −0.06 (−0.16, 0.03)       0.18      26%
                                                                North America                          9,438                                       0.82 (0.65, 1.00)                        2.7×10^−21^          38,500    0.34 (0.25, 0.44)    6.1×10^−12^   47,938    −0.49 (−0.65, −0.33)   1.6×10^−9^   0%
                                                                    Asia                               1,121                                       0.78 (0.14, 1.43)                           0.017              4,800    0.53 (0.32, 0.75)    1.0×10^−6^     5,921    −0.37 (−0.86, 0.13)       0.15      0%
  **Waist circumference (cm)**                                 All individuals                         38,560                                      1.01 (0.80, 1.22)                        2.6×10^−21^          121,288   0.68 (0.58, 0.79)    9.2×10^−35^   159,848   −0.33 (−0.54, −0.12)     0.0018     5%
                                                                   Europe                              32,519                                      0.87 (0.65, 1.09)                        1.2×10^−14^          96,292    0.65 (0.55, 0.75)    1.4×10^−35^   128,811   −0.22 (−0.44, 0.00)      0.049      4%
                                                                North America                          4,921                                       1.72 (1.16, 2.28)                         1.4×10^−9^          20,196    0.65 (0.30, 1.01)    3.2×10^−4^    25,117    −1.02 (−1.60, −0.45)   4.6×10^−4^   0%
                                                                    Asia                               1,120                                       1.65 (0.80, 1.22)                           0.029              4,800    1.12 (0.61, 1.62)    1.5×10^−5^     5,920    −0.84 (−2.03, 0.35)       0.16      0%
  **Body fat percentage (%)**                                  All individuals                         11,839                                      0.44 (0.30, 0.58)                        1.0×101^−9^          49,670    0.28 (0.20, 0.37)    9.4×10^−12^   61,509    −0.19 (−0.35, −0.04)     0.016      0%
                                                                   Europe                              11,658                                      0.43 (0.29, 0.57)                         3.1×10^−9^          48,959    0.29 (0.20, 0.38)    4.8×10^−10^   60,617    −0.18 (−0.34, −0.03)     0.023      0%
                                                                North America                           181                                        2.03 (0.35, 3.70)                           0.018               711     0.48 (−0.26, 1.22)      0.20         892     −1.57 (−3.34, 0.20)      0.082      0%
                                                                    Asia                                 NA                                                NA                                    NA                NA              NA               NA          NA               NA                NA       NA
  **Risk of obesity (BMI ≥30 versus BMI \<25 kg/m^2^)**        All individuals                         32,774                                      1.30 (1.24, 1.36)                        1.1×10^−29^          97,779    1.22 (1.19, 1.25)    1.0×10^−46^   131,474    0.92 (0.88, 0.97)       0.0010     5%
                                                                   Europe                              26,139                                      1.27 (1.22, 1.33)                        2.9×10^−29^          71,738    1.21 (1.17, 1.25)    9.1×10^−35^   97,877     0.94 (0.90, 0.99)       0.028      0%
                                                                North America                          5,777                                       1.43 (1.28, 1.60)                        6.0×10^−10^          23,505    1.22 (1.15, 1.30)    1.0×10^−9^    29,282     0.85 (0.75, 0.98)       0.024      24%
                                                                    Asia                                858                                        1.86 (1.17, 2.93)                           0.0082             3,457    1.41 (1.18, 1.70)    1.9×10^−4^     4,315     0.74 (0.46, 1.20)        0.23      0%
  **Risk of overweight (BMI ≥25 versus BMI \<25 kg/m^2^)**     All individuals                         53,726                                      1.19 (1.15, 1.23)                        2.0×10^−22^          159,838   1.14 (1.12, 1.16)    2.1×10^−42^   213,564    0.95 (0.91, 0.99)       0.015      20%
                                                                   Europe                              43,833                                      1.17 (1.13, 1.20)                        5.8×10^−26^          119,236   1.14 (1.11, 1.16)    3.2×10^−29^   163,069    0.96 (0.92, 1.01)       0.090      14%
                                                                North America                          8,772                                       1.24 (1.11, 1.39)                         1.8×10^−4^          35,802    1.13 (1.09, 1.17)    1.0×10^−12^   44,574     0.89 (0.80, 0.99)       0.034      21%
                                                                    Asia                               1,121                                       1.21 (0.79, 1.87)                            0.38              4,800    1.26 (1.13, 1.41)    4.9×10^−5^     5,921     0.99 (0.67, 1.48)        0.98      50%

All models are adjusted for age and sex. Beta is the increase in trait per minor allele of rs9939609 or a proxy (*r* ^2^\>0.8); beta~interaction~ is the difference in trait per minor allele of rs9939069 comparing physically active individuals to inactive individuals, e.g., a beta~interaction~ of −0.14 kg/m^2^ for BMI represents a 0.14 kg/m^2^ attenuation in the BMI-increasing effect of the rs9939609 minor allele in physically active individuals compared to inactive individuals; *I* ^2^ is the heterogeneity between studies in the meta-analysis; interaction OR is the ratio of ORs (OR\[physically active\]/OR\[inactive\]) per minor allele of rs9939609, e.g., an interaction OR of 0.92 for risk of obesity indicates that the obesity-increasing effect of the rs9939609 minor allele in physically active individuals is 0.92 of the effect in inactive individuals.

Values are beta/beta~interaction~ for all rows except risk of obesity and risk of overweight, for which values are OR/interaction OR.

NA, no data available for analysis.

To examine the sources of heterogeneity between studies, which was moderate (*I* ^2^ = 36%) ([Table 2](#pmed-1001116-t002){ref-type="table"}; [Figure 2](#pmed-1001116-g002){ref-type="fig"}), we used meta-regression. The meta-regression indicated heterogeneity by geographic region (North America versus Europe) in the interaction (*p = *0.001) ([Tables S4](#pmed.1001116.s013){ref-type="supplementary-material"} and [S5](#pmed.1001116.s014){ref-type="supplementary-material"}). When we subsequently stratified our meta-analysis by geographic region, the attenuating effect of PA on the association between the *FTO* variant and BMI was more pronounced in North American populations than in European populations (*p* ~difference~  = 5×10^−6^) ([Table 2](#pmed-1001116-t002){ref-type="table"}; [Figure 2](#pmed-1001116-g002){ref-type="fig"}). More specifically, the BMI-increasing effect of the *FTO* risk allele in physically active North Americans was 59% smaller than in inactive North Americans (beta  = 0.34 versus 0.82 kg/m^2^, respectively), whereas the attenuation in the BMI-increasing effect of the risk allele in physically active Europeans compared with inactive Europeans was only 19% (beta  = 0.30 versus 0.37 kg/m^2^, respectively) ([Table 2](#pmed-1001116-t002){ref-type="table"}). There was no heterogeneity among North American studies (*I* ^2^ = 0%), whereas moderate heterogeneity was observed among European studies (*I* ^2^ = 26%) ([Table 2](#pmed-1001116-t002){ref-type="table"}; [Figure 2](#pmed-1001116-g002){ref-type="fig"}). In a further sub-group meta-regression, none of the covariates explained a significant proportion of the remaining heterogeneity observed in Europeans.

To test for the presence of "positive results bias" (i.e., whether studies with positive results were more likely to participate in our meta-analysis than those with negative or inconclusive results), we drew a funnel plot of the interaction beta coefficients and standard errors and conducted Begg and Egger tests for bias. The funnel plot was symmetrical, and the results for Begg and Egger tests were non-significant (*p = *0.9 and *p = *0.8, respectively), indicating that our results were not affected by positive results bias ([Figure S1](#pmed.1001116.s001){ref-type="supplementary-material"}).

While we observed a strong effect of the *FTO* risk allele on BMI in children and adolescents ([Table S3](#pmed.1001116.s012){ref-type="supplementary-material"}), this effect was not modified by their PA level (*p* ~interaction~  = 0.98) ([Figure 3](#pmed-1001116-g003){ref-type="fig"}). There was no heterogeneity between the studies (*I* ^2^ = 1%).

![Forest plot of the effect of the interaction between the *FTO* rs9939609 SNP and physical activity on BMI in a random effects meta-analysis of 19,268 children and adolescents.\
The studies are sorted by sample size (largest sample size lowest). Details of the studies are given in [Text S1](#pmed.1001116.s015){ref-type="supplementary-material"}. The interaction *Z*-score represents the difference in age- and sex-standardized BMI per minor (A−) allele of rs9939609 comparing physically active children to inactive children. For example, a beta~interaction~ of −0.1 represents a 0.1 unit attenuation in the BMI *Z*-score-increasing effect of the rs9939609 minor allele in physically active children compared to inactive children.](pmed.1001116.g003){#pmed-1001116-g003}

### *FTO*×PA interaction and risk of obesity and overweight {#s3d2}

Consistent with the meta-analysis of BMI, PA attenuated the effect of the *FTO* risk allele on the odds of obesity (*p* ~interaction~  = 0.001) and on the odds of overweight (*p* ~interaction~  = 0.02) ([Table 2](#pmed-1001116-t002){ref-type="table"}; [Figures S2](#pmed.1001116.s002){ref-type="supplementary-material"} and [S3](#pmed.1001116.s003){ref-type="supplementary-material"}). The odds of obesity for the *FTO* risk allele were 27% smaller (odds ratio \[OR\] = 1.22 versus 1.30, respectively) and the odds of overweight were 26% smaller (OR = 1.14 versus 1.19, respectively) in physically active individuals than in inactive individuals ([Table 2](#pmed-1001116-t002){ref-type="table"}). Similar to the results for BMI, there seemed to be a more pronounced *FTO*×PA interaction effect in North American populations than in Europeans: the risk-attenuating effect of PA was more than double in North Americans compared to Europeans ([Table 2](#pmed-1001116-t002){ref-type="table"}; [Figures S2](#pmed.1001116.s002){ref-type="supplementary-material"} and [S3](#pmed.1001116.s003){ref-type="supplementary-material"}). The differences in the interaction effect between North Americans and Europeans on the odds of obesity and overweight were, however, not significant (*p* ~difference~  = 0.2 for both obesity and overweight).

### *FTO*×PA interaction on waist circumference and body fat percentage {#s3d3}

We observed a significant effect of the *FTO*×PA interaction on waist circumference (beta~interaction~  = −0.33 cm, *p* ~interaction~  = 0.002) and body fat percentage (beta~interaction~  = −0.19%, *p* ~interaction~  =  0.02) ([Table 2](#pmed-1001116-t002){ref-type="table"}; [Figures S4](#pmed.1001116.s004){ref-type="supplementary-material"} and [S5](#pmed.1001116.s005){ref-type="supplementary-material"}). The influence of the *FTO* risk allele on waist circumference was 33% smaller and the influence on body fat percentage 36% smaller in physically active individuals than in inactive individuals ([Table 2](#pmed-1001116-t002){ref-type="table"}). Similar to the results for BMI, the effect of the *FTO*×PA interaction on waist circumference was also more pronounced in North American populations (beta~interaction~  =  −1.02 cm) than in Europeans (beta~interaction~  =  −0.22 cm) (*p* ~difference~  =  0.01) ([Table 2](#pmed-1001116-t002){ref-type="table"}; [Figure S4](#pmed.1001116.s004){ref-type="supplementary-material"}). We found a similar difference for body fat percentage (beta~interaction~  =  −1.57% in North Americans versus beta~interaction~  =  −0.18% in Europeans) that, however, did not reach significance (*p* ~difference~  = 0.1), but few North American individuals had data on body fat percentage (*n = *892) ([Table 2](#pmed-1001116-t002){ref-type="table"}; [Figure S5](#pmed.1001116.s005){ref-type="supplementary-material"}).

The effect of the *FTO* risk allele on waist circumference and body fat percentage in children and adolescents was not modified by their PA level (*p* ~interaction~  = 0.7 and 0.4, respectively) ([Figures S6](#pmed.1001116.s006){ref-type="supplementary-material"} and [S7](#pmed.1001116.s007){ref-type="supplementary-material"}). There was no heterogeneity between the studies in these meta-analyses (*I* ^2^  =  0%).

Association of *FTO* with Physical Activity {#s3e}
-------------------------------------------

There was no association between *FTO* and the level of PA in adults (*p = *0.2) ([Figure S8](#pmed.1001116.s008){ref-type="supplementary-material"}) or children (*p = *0.6) ([Figure S9](#pmed.1001116.s009){ref-type="supplementary-material"}). No between-study heterogeneity was found in these meta-analyses either (*I* ^2^≤1%).

Discussion {#s4}
==========

By combining data from 218,166 adults from 45 studies, we confirm that PA attenuates the influence of *FTO* variation on BMI and obesity. The association of the *FTO* rs9939609 variant with BMI and with the odds of obesity was reduced by approximately 30% in physically active compared to inactive adults. We also found an interaction effect on the odds of overweight and on waist circumference and body fat percentage. No interaction between *FTO* and PA was found in our meta-analysis of 19,268 children and adolescents.

Our findings are highly relevant for public health. They emphasize that PA is a particularly effective way of controlling body weight in individuals with a genetic predisposition towards obesity and thus contrast with the determinist view held by many that genetic influences are unmodifiable. While our findings carry an important public health message for the population in general, they do not have an immediate impact at the individual level. More specifically, targeting PA interventions based on *FTO* genotype screening only would not accurately identify those who would benefit most of such intervention, as the effect of the *FTO* variant on body weight is relatively small (∼1 kg) and the attenuation of this effect by PA is limited. Of interest is that current evidence does not suggest that genetic testing would lead to an increased motivation of individuals to improve their lifestyle [@pmed.1001116-Bloss1]. On the contrary, a recent study suggests that those shown to be genetically susceptible to obesity may even worsen their dietary habits [@pmed.1001116-Bloss1]. Convincing evidence of gene--lifestyle interactions, however, might give people a sense of control that risk-reducing behaviors can be effective in prevention. Thus, identifying interactions between genes and lifestyle is important as it demonstrates that a genetic susceptibility to obesity is modifiable by lifestyle. Furthermore, insights from gene--lifestyle interactions contribute to elucidating the mechanisms behind genetic regulation of obesity, which may help in the development of new treatments in the future.

Interestingly, we found a geographic difference in the interaction of *FTO* with PA, which was consistent across the studied phenotypes. In particular, the interaction was stronger in North American populations than in populations from Europe. Reasons for the observed geographic difference are unclear. As the participating North American and European studies are mainly representative of individuals of European descent, genetic differences between them are small and unlikely to substantially contribute to the observed difference in the interaction. However, we speculate that the geographic difference may, at least in part, be related to the lower average levels of PA in individuals living in North America than in Europe [@pmed.1001116-Friedenreich1],[@pmed.1001116-Hagstrmer1]. The *FTO*×PA interaction effect may materialize more in populations with a high prevalence of very sedentary individuals [@pmed.1001116-Vimaleswaran1]. Furthermore, sedentariness may also associate with other lifestyle factors that may contribute to the interaction, such as unhealthy diet [@pmed.1001116-Sonestedt1],[@pmed.1001116-Sonestedt2],[@pmed.1001116-Ahmad1], which we were not able to adjust for in our meta-analyses and which may be more prevalent in North American populations than in Europeans [@pmed.1001116-Powell1]. Finally, there were differences in the measurement methods used to assess PA between North American and European studies. More specifically, all North American studies quantified PA using a continuous PA variable, whereas many European studies used categorical variables. As a result, the overall number of individuals defined as inactive was smaller in North American (20%) than in European studies (27%). We also found that PA was associated with a 1.34 kg/m^2^ lower BMI in North American populations, but with only a 0.72 kg/m^2^ lower BMI in Europeans. As misclassification in exposure measurements usually biases the effect towards the null, it is possible that lower accuracy of PA measurements in European studies may have deflated the effect of PA on BMI, as well as the interaction between *FTO* and PA. In our meta-regressions, however, we did not find a significant association between the measurement of PA and the observed *FTO*×PA interaction effect ([Tables S4](#pmed.1001116.s013){ref-type="supplementary-material"} and [S5](#pmed.1001116.s014){ref-type="supplementary-material"}). Nevertheless, it is likely that our overall effect estimate for the interaction is a considerable underestimate of the true effect because of measurement error of PA.

In studies with continuous measures of PA, we chose to use a definition of "inactivity" based on a relative (lowest 20%) cut-off of PA levels. The use of a cut-off based on fixed percentage may have introduced heterogeneity as the percentage may correspond to different absolute PA values in the participating studies. However, the use of an absolute cut-off might have led to even greater heterogeneity, because of the wide differences in the measurement instruments that were used to provide the continuous measures of PA. In theory, the accuracy of a relative PA cut-off could be improved by choosing a specific cut-off for each country on the basis of national PA data. In practice, however, comparing PA data between countries is difficult, as prevalence estimates for sedentariness have been assessed by different survey instruments, which sometimes have also changed over time, and prevalence estimates are not always available from representative samples of the population.

The present meta-analysis was based on cross-sectional data and thus does not provide information on the longitudinal relationships between variables. While germline DNA remains stable throughout the life course, PA levels may change and may be confounded by other lifestyle and environmental factors that correlate with PA and body weight. So far, only three prospective follow-up studies (*n* ~range~  = 502 to 15,844) on the interaction between *FTO* and PA have been reported, and none showed an interaction between *FTO* and baseline PA, or change in PA, on weight change during follow-up [@pmed.1001116-Jonsson1]--[@pmed.1001116-Lappalainen1]. Although studies investigating PA alone did not find an interaction, the Diabetes Prevention Program in the US showed an interaction between *FTO* and a 1-y lifestyle intervention, consisting of PA, diet, and weight loss combined, on change in subcutaneous fat area among 869 individuals [@pmed.1001116-Franks1]. The minor allele of the *FTO* variant was associated with an increase in subcutaneous fat area in the control group but not in the lifestyle intervention group [@pmed.1001116-Franks1]. Two studies have tested whether *FTO* modified the effect of a standardized exercise program on change in body weight in individuals who were sedentary at baseline, but results were inconsistent. While the first study showed a greater weight loss for the carriers of the major (C−) allele of *FTO* rs8050136 after a 20-wk endurance training program among 481 men and women [@pmed.1001116-Rankinen1], a subsequent study with a 6-mo endurance training program among 234 women indicated weight loss benefits for the carriers of the minor (A−) allele of the same variant [@pmed.1001116-Mitchell1]. These studies may have been insufficiently powered to detect an interaction between *FTO* variation and exercise intervention. A meta-analysis of prospective studies may be required to confirm or refute whether there is an interaction between changes in PA and *FTO* on weight gain in a sufficiently powered population sample. Finally, a large-scale randomized controlled trial would be needed to infer causality for the interaction between PA and *FTO*.

We found no interaction between the *FTO* variant and PA on BMI in children and adolescents, which could be because of low statistical power, as the sample size was 11 times smaller than in the meta-analysis of adults. Even so, the effect size of the interaction was null, suggesting that no attenuation of PA on the BMI-increasing effect of *FTO* would be found, even if a larger sample was meta-analyzed. The lack of interaction in children may, at least in part, be due to the weak association between PA and childhood BMI and the higher activity levels in children than in adults [@pmed.1001116-Troiano1]. Despite the fact that BMI is a noninvasive and easy-to-obtain measure of adiposity, its weakness is that it does not distinguish lean body mass from fat mass and may therefore not be the best measure of adiposity in children. Indeed, the associations of PA with waist circumference and body fat percentage were significant, and the effect of the *FTO*×PA interaction on body fat percentage pointed towards a slightly decreased effect of the *FTO* risk allele in physically active children as compared to sedentary children.

We designed a meta-analysis based on a de novo analysis of data according to a standardized plan in all studies identified as having available data. The analytical consistency across studies, which helped minimize between-study heterogeneity, and the pooling of all identified data, which minimized biases related to study selection, are major strengths of our meta-analysis. A greater consistency and statistical power could ultimately be reached only through the establishment of large single or multicenter studies using standardized methods and precise measurement of PA.

In summary, we have established that PA attenuates the association of the *FTO* gene with adult BMI and obesity by approximately 30%. We have also demonstrated that large-scale international collaborations are useful for confirming interactions between genes and lifestyle.
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